Google is adding new health features to its wearables, including a tool that tracks insulin-resistance trends over time, according to Bloomberg. The report says the feature is coming to Google’s Watch 5 and Fitbit Air, while Techmeme’s aggregation of the Bloomberg report describes the rollout more broadly as launching first on the Watch 5 and Fitbit devices. The feature is notable because Bloomberg frames it as a first among consumer technology companies trying to move closer to comprehensive blood-sugar monitoring. The summaries do not say that Google is offering direct blood-glucose measurement, nor do they establish that the feature is a diagnostic tool. Techmeme’s summary of Bloomberg says the insulin-resistance trend feature uses artificial intelligence, an accelerometer, and other sensors. The available summaries do not provide more detail on the model, the sensor package, how frequently the trend is calculated, or what claims Google is making about accuracy. The direction is clear: Google is positioning its wearables deeper into metabolic-health tracking, an area adjacent to one of the harder unsolved problems in consumer health hardware. Comprehensive blood-sugar monitoring has been a major target for device makers, but the provided Bloomberg summary describes Google’s move as tracking insulin-resistance trends over time, not as cracking continuous glucose monitoring. For readers evaluating the business impact, the key distinction is between a trend feature and a regulated medical measurement. The summaries support the former. They do not say whether the feature requires clearance, whether it will be limited by geography, or whether Google will market it as wellness guidance rather than medical information. Who benefits: Google benefits if the feature gives Watch 5 and Fitbit Air a clearer health-data use case. Users interested in long-term metabolic-health signals may also benefit, depending on how Google presents and validates the trend data. Who's exposed: Rival wearable makers are exposed to the extent that metabolic-health tracking becomes a competitive feature category. It is too early from the provided summaries to assess exposure for medical-device companies or glucose-monitoring incumbents.